Pharmaceutical giant H. Lundbeck was fined by the European Commission just last year for a pay-for-delay scheme, but now the company is facing antitrust scrutiny from its home country of Denmark.
Reports say H. Lundbeck, which was fined last year by the Commission for paying to have a generic form of its antidepressant Celexa from entering the market, is now under fire by various healthcare providers seeking counsel by the attorney general over whether they can pursue claims against the firm.
This time, say reports, H. Lundbeck is in a spat with generic drug maker Actavis regarding the antidepressant Cipralex. While Actavis argues H. Lundbeck is hampering competition, H. Lundbeck is accusing Actavis of violating its patents.
The feud comes after European Commission fined H. Lundbeck nearly $200 million for the so-called pay-for-delay scheme in 2013.
Full Content: Fierce Pharma
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Uruguayan Antitrust Scrutiny Puts Major Meatpacking Deal Between Marfrig and Minerva on Hold
May 19, 2024 by
CPI
Alaska Airlines Seeks Dismissal of Consumer Lawsuit Over $1.9 Billion Hawaiian Airlines Buy
May 19, 2024 by
CPI
Idaho Attorney General Orders Split of Kootenai Health and Syringa Hospital
May 19, 2024 by
CPI
Court Rejects T-Mobile’s Appeal Bid in Antitrust Case Over Sprint Merger
May 19, 2024 by
CPI
Google Requests Judge, Not Jury, to Decide on Antitrust Case
May 19, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI